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ABSTRACT: In this work, we employed broad-band dielectric spectroscopy to
determine the solubility limits of nimesulide in the Kollidon VA64 matrix at ambient
and elevated pressure conditions. Our studies confirmed that the solubility of the drug
in the polymer matrix decreases with increasing pressure, and molecular dynamics
controls the process of recrystallization of the excess of amorphous nimesulide from
the supersaturated drug−polymer solution. More precisely, recrystallization initiated at
a certain structural relaxation time of the sample stops when a molecular mobility
different from the initial one is reached, regardless of the temperature and pressure
conditions. Finally, based on the presented results, one can conclude that by
transposing vertically the results obtained at elevated pressures, one can obtain the
solubility limit values corresponding to low temperatures. This approach was validated
by the comparison of the experimentally determined points with the theoretically
obtained values based on the Flory−Huggins theory.
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■ INTRODUCTION
Developing a drug as an amorphous solid dispersion (ASD)
has many benefits as over 80% of ASDs offers better
bioavailability compared to the crystalline form of the active
substance.1 However, one should keep in mind that this is not
an easy task. The main challenge lies in identifying the optimal
ratio between the active pharmaceutical ingredient (API) and
the polymer, which provides the best dissolution, while
maintaining the physical stability of the ASD. It should be
highlighted that one can ensure the physical stability of the
API−polymer mixture from a thermodynamic point of view.
To do so, two main requirements must be met. The most
important factor is to appropriately select the ingredients in a
way to ensure that the drug can be dissolved in a polymer
matrix as their mutual solubility/miscibility plays a key role.
Next, it is to use the amount of the API, which does not exceed
the solubility limit in a given polymer; thus, the API
concentration must be maintained below the saturation
level.2−6 Thus, the best approach to developing stable
amorphous drug−polymer systems seems to be the determi-
nation of the solubility limit of the drug in a given polymer in
advance. This will allow to identify the maximum amount of
API that can be used without compromising the amorphous
nature of the drug during the shelf-life.
A number of experimental approaches exploring the subject
of drug−polymer solubility have been proposed.2,7−13
However, these methods are burdened with certain limitations.
Solubility in small-molecule solutions is defined as an
equilibrium thermodynamic parameter, that is, the chemical
potential of the solute in the solid phase is the same as that in
the liquid phase. One can extend this definition for polymer
solvents supposing that equilibrium can be reached when the
measurement is performed well above the Tg of the system.
Thus, when the temperature is equal or lower than the glass-
transition temperature (Tg), the API−polymer system
becomes too viscous to maintain the equilibrium. Therefore,
the experimentally determined solubility in the context of
amorphous substances is defined as the “apparent” solubil-
ity.9,12,13 However, it should be pointed out that there is a way
to predict, at a broad temperature range (even to the extent
not available experimentally), the solubility of an API in the
polymer matrix. The most commonly used theoretical
approaches are based on either (i) perturbed-chain statistical
associating fluid theory14−16 or (ii) the Flory−Huggins (FH)
theory.17−22
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Hot-melt extrusion (HME) is a processing technique
suitable for the production of ASDs for pharmaceutical
applications.23−25 During the extrusion, a mix of the crystalline
drug and the chosen polymer (raw materials) is subjected to
shearing and intense mixing of a rotating screw under an
elevated temperature and pushed through a die to obtain a
product of homogeneous shape.26,27 The pressures generated
within an extruder can reach very high values (up to 70
MPa).28 There are a number of reports addressing the
compression-induced recrystallization of amorphous APIs, at
conditions corresponding to the pressure exerted during
extrusion.29−31 A good example of the discussed phenomenon
is the study conducted on amorphous probucol. The authors
confirmed that the amorphous drug does not exhibit any
tendency toward devitrification up to the point where the
elevated pressure was applied. A compression force equal to 10
MPa immediately induced devitrification of the amorphous
API. Interestingly, once recrystallization started, the process
progressed even when the initial crystallization-inducing factor
was no longer present (when the sample was decompressed).32
Due to the fact that probucol was classified as a pressure-
controlled compound,33 other drugs in this group might, but
not necessarily, have to display a similar behavior. Another
example of the drug with a well-documented sensitivity to
elevated pressure is bicalutamide.34,35 Szafraniec-Szczes̨ny et al.
have shown that the tendency of amorphous bicalutamide
toward recrystallization increases with the increasing com-
pression force,36 thus confirming the importance of the
pressure factor when considering the stability of amorphous
systems.
The latest studies have revealed information about the effect
of the increased pressure on the earlier discussed solubility
limit.37,38 However, our knowledge of this phenomenon is still
limited. It should be noted that a simple comparison of the
number of reports addressing the subject of drug−polymer
solubility under ambient pressure conditions with those
considering the effect of increased pressure reveals a substantial
disproportion. This is surprising considering extrusion-based
drug formulations.
In this paper, we determined the solubility limits of
nimesulide (NMS) in the Kollidon VA64 (KVA) matrix at
both ambient and elevated pressure conditions, starting from
the supersaturated solutions. Most of the experimental
approaches employed to determine the solubility limit are
based on calorimetric measurements.2,7−13 Nevertheless, the
results presented herein were obtained with the use of both
differential scanning calorimetry (DSC) and broad-band
dielectric spectroscopy (BDS). BDS is an experimental
technique already applied to determine the solubility limit at
ambient pressure.39−43 Moreover, due to the fact that this
method has been repeatedly used to test amorphous materials
under elevated pressures,32,44 in particular, as it has been
recently shown to determine the aforementioned solubility
under elevated pressure conditions,37,38 we chose it as the main
experimental technique.
The aim of our investigations was to find the answer to the
following question: How important are the solubility limit
studies performed at elevated pressures and can we translate
them to ambient pressure conditions? To achieve this goal, we
conducted a series of DSC and BDS measurements. The
thermal properties of ASDs containing various concentrations
of NMS and KVA were investigated by DSC. The molecular
mobility of the prepared drug−polymer mixtures, which was
later used to determine the solubility limits at both ambient
and elevated pressures, was measured by means of BDS.
Furthermore, isothermal and nonisothermal measurements
allowed us to determine the concentration dependencies of Tg
of NMS + KVA systems.
■ EXPERIMENTAL SECTION
Materials. NMS with molecular weight MW = 308.31 g
mol−1 and purity ≥ 99% was supplied by Kemprotec Limited
(UK). Polyvinylpyrrolidone vinylacetate−Kollidon VA64
(KVA) of molecular mass MW = 45,000−47,000 g mol−1 was
purchased from BASF SE (Ludwigshafen, Germany). The
NMS and KVA samples were received as a light-yellow and
white powder, respectively. Both NMS and KVA were used
without further purification.
Preparation of Binary Systems. To acquire homoge-
neous samples, the API and the polymer were mixed at
appropriate ratios in a mortar. The sample preparation for
ambient and high-pressure BDS measurements involved
melting at T = 433 K followed by vitrification on a previously
chilled copper plate. All measurements were performed
immediately after the preparation of the amorphous systems
to avoid recrystallization.
Differential Scanning Calorimetry. The thermal proper-
ties of NMS-based ASDs were examined using a Mettler-
Toledo DSC 1 STARe System (Columbus, OH, USA). The
measuring device was equipped with a HSS8 ceramic sensor
with 120 thermocouples. The instrument was calibrated for
temperature and enthalpy using indium and zinc standards.
Crystallization and melting points were determined as the
onset of the peak, whereas the glass-transition temperature as
the midpoint of the heat capacity increment. The samples were
measured in a closed aluminum crucible (40 μL) with a
pinhole to prevent the buildup of pressure. Amorphous
samples were obtained in situ in the DSC apparatus by fast
cooling (at the rate of 20 K/min) of the previously melted
sample (data not shown). All measurements were carried out
in the range from 270 to 433 K using a 10 K/min heating rate
and a 20 K/min cooling rate under a nitrogen purge (60 mL/
min).
Broad-band Dielectric Spectroscopy. The dielectric
measurements of NMS-based ASDs were carried out using a
Novo-Control GMBH Alpha dielectric spectrometer (Mon-
tabaur, Germany) in the frequency range from 10−1 to 106 Hz
at preselected temperatures at a heating rate of 2 K/min (and a
cooling rate of 50 K/min in case of quenching samples on a
copper plate after melting and 10 K/min after annealing at
certain temperatures). The temperature was controlled by a
Quatro temperature controller with temperature stability better
than 0.1 K. Dielectric studies of NMS and NMS + KVA binary
systems were performed immediately after their vitrification by
the fast cooling of the melt in a parallel-plate cell made of
stainless steel (15 mm diameter and 0.1 mm gap with a quartz
spacer).
For high-pressure BDS measurements, a high-pressure
Unipress U111 setup (Warszawa, Poland) was additionally
employed. For these experiments, the sample was measured in
a similar parallel-plate cell made of stainless steel (15 mm
diameter and 0.1 mm gap with a Teflon spacer). The cell was
then sealed and encased in a Teflon tape to separate it from the
silicon liquid. The temperature was adjusted with a precision of
0.1 K by a Julabo heating circulator (Seelbach, Germany).
The protocol used to determine solubility was as follows:45
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(i) In the first step, a strongly supersaturated glass solution
is formed. First, a physical mix is obtained by mixing the
API and polymer at appropriate ratios in a mortar for 20
min to acquire a homogeneous sample. Then, for both
ambient and high-pressure measurements, the sample is
melted and vitrified using well-defined heating and
cooling rates.
(ii) The supersaturated glass solution is then loaded into a
DSC/BDS instrument and annealed above its glass-
transition temperature to reach the equilibrium concen-
tration at the annealing temperature. Depending on the
sample and measuring technique, a sufficient annealing
time must be determined to reach this equilibrium
concentration in a wide range of annealing temperatures.
In this work, this annealing time was up to 50 and 70 h
for DSC and BDS measurements, respectively. This
difference was mainly due to the geometry of the
container used in both experiments, as it is one of the
factors affecting the beginning and progress of the
crystallization process.46
(iii) In the third step, the equilibrium concentration of the
drug remaining in the polymer matrix after annealing is
determined. This is done by determining the glass-
transition temperature of the annealed material by DSC/
BDS.
(iv) The last step is determination of the sample composition
by comparing its glass transition to the experimentally
determined compositional dependence of Tg’s (deter-
mined for each measuring technique independently).
By repeating steps (ii−iv) for different annealing temper-
atures, it is possible to determine the solubility curve.
True Density Measurements. The true density of
amorphous NMS was measured by an AccuPyc 1330
pycnometer, Micromeritics, using helium (99.995% purity)
to determine the volume of the sample.19 A 1 cm3 aluminum
sample cup was used. The instrument was calibrated
immediately before the analysis, and the measurement
comprising five volume determinations was performed in
duplicate.
Mathematical Modeling.Modeling of the phase diagrams
and statistical analysis were performed in Origin 2018.
Nonlinear least-squares curve fits to experimentally determined
data were obtained by applying the Levenberg−Marquardt
iteration algorithm until the Chi-square tolerance value of 1 ×
10−9 was reached and the fit converged.19 No weighting for the
parameters was applied.
■ RESULTS AND DISCUSSION
Determination of the Solubility Limits of the NMS +
KVA ASD via Calorimetric Measurements. The thermal
properties of neat NMS have been already documented in the
literature;47 therefore, we focused mainly on its binary systems.
The thermograms of the amorphous NMS + KVA mixtures at
various weight concentrations (after melting and quenching in
the DSC apparatus), obtained through measurements carried
out in the range from 270 to 433 K at the 10 K/min heating
rate, are presented in panel (a) of Figure 1. All measured
systems are characterized by a single-step thermal event that
corresponds to the glass transition. Considering the work of
Baird and Taylor, the presence of two separate Tg’s during the
standard DSC measurement would correspond to the phase
separation in the sample.48 Therefore, the obtained results
imply the homogeneity of the systems.49,50 The exact values of
Tg are as follows: 294 K (NMS),
47 303 K (NMS + 20 wt %
KVA), 312 K (NMS + 30 wt % KVA), 321 K (NMS + 40 wt %
KVA), 335 K (NMS + 55 wt % KVA), 355 K (NMS + 80 wt %
KVA), and 377 K (KVA).
One can observe a continuous evolution of Tg with the
increasing amount of the polymer in the system. This
phenomenon is common, and its origin can be explained by
either the antiplasticization effect exerted by the addition of the
polymer with a higher Tg value than that of a neat amorphous
drug or the specific interactions between the components.51 If
the antiplasticization effect is dominant, Tg of the mixtures
should vary with the polymer content in accordance to the
Gordon−Taylor (G−T) prediction, which is defined as follows
Figure 1. (a) Thermograms of amorphous: NMS47 (orange), NMS + 20 wt % KVA (pink), NMS + 30 wt % KVA (raspberry), NMS + 40 wt %
KVA (red), NMS + 55 wt % KVA (cardinal), NMS + 80 wt % KVA (burgundy), and KVA (black). (b) Glass-transition temperatures of NMS +
KVA mixtures. Diamonds correspond to the experimentally determined Tg values, while the orange pentagon (NMS) represents the experimental
data corresponding to the literature. The dashed line represents the Gordon−Taylor prediction.
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where Tg, Tg1, and Tg2 are the glass-transition temperatures of
the drug−polymer mixture, the amorphous drug, and the
polymer, respectively; W1 and W2 are the weight fractions of
the drug and the polymer, respectively; and K is a parameter











where ΔCp1 and ΔCp2 are the changes in heat capacity at Tg of
the drug and polymer, respectively. In panel (b) of Figure 1, Tg
values predicted from the G−T equation (eq 1) (marked as
black dashed line) were compared with the experimentally
obtained Tg’s of the NMS + KVA systems containing various
polymer concentrations (marked as diamonds). It can be seen
that they are in good agreement. Such a result indicates that
the drug should be miscible and homogeneously dispersed in
the polymer.52 This is of importance as highly miscible systems
are usually characterized by better physical stability. It should
be noted that although it is not a conclusive proof, no
significant deviation of the experimental points from the G−T
prediction suggests the lack of any specific strong drug−
polymer interactions.52
The determination of the solubility limit presented in this
work, regardless of the applied experimental technique
(whether calorimetric or dielectric), is based on Mahieu’s
approach.2 The amorphous NMS + 40 wt % KVA system was
arbitrarily chosen for the subsequent solubility limit studies as
the supersaturated starting composition. According to the
protocol proposed in ref 2, the samples were annealed at the
following temperatures: 368, 373, 378, 383, 388, 393, and 398
K for up to 50 h and then cooled down and re-measured by
DSC to determine Tg. Panel (a) of Figure 2 shows
representative examples of the samples re-measured after
isothermal recrystallization at four out of seven temperatures
selected above.
Determination of the exact concentration of the remaining
amorphous systems after recrystallization was possible based
on the obtained Tg values. This can be done by the simple
comparison of these values to either the experimentally
determined dependency of Tg on the concentration or to the
G−T prediction, as no discrepancies between them were
noticed [see panel (b) of Figure 2]. Both the Tg’s as well as
solubility limit values determined after the recrystallization of
the excess amount of drug from the NMS + 40 wt % KVA
mixture are collected in Table 1. The obtained results served as
a verification of the data obtained from the dielectric studies.
Determination of the Solubility Limits of the NMS +
KVA ASD via Dielectric Measurements at Ambient
Pressure Conditions. Similar to the solubility limits
determined by DSC, the experimental determination of the
concentration dependency of the glass-transition temperature
was first determined by BDS. This dependence was then used
to identify the compositions obtained after recrystallization.
For this purpose, the analysis of the molecular mobility of each
prepared sample was undertaken as a series of BDS
measurements. The representative dielectric loss spectra of
the NMS + 40 wt % KVA mixture, which were obtained during
the heating of the amorphous sample, above its Tg, are shown
in Figure 3. The spectra showed one loss peak corresponding
to the structural α relaxation. The maximum of this peak
moves toward higher frequencies with the increasing temper-
ature. The intensity of this peak [its dielectric strength (Δε)] is
proportional to the number of units involved in the structural
relaxation. Therefore, a sudden drop of Δε would reflect the
onset of the sample recrystallization.53,54 Due to the fact that
no sudden drop in intensity was observed on the dielectric loss
spectra up to 393 K, one can assume that the recrystallization
process did not occur during nonisothermal experiments (see
Figure 3). This can indicate the relatively high physical stability
of the NMS-based ASD containing not less than 40 wt % of
KVA.
From the analysis of the loss spectra collected above Tg, we
determined the temperature dependencies of the α-relaxation
times for all the measured systems [see panel (a) of Figure 4].
To obtain the values of τα at various temperatures, the
experimental data were fitted using the Havriliak−Negami
(HN) function (eq 3)55
Figure 2. (a) Thermograms of the fully amorphous NMS + 40 wt %
KVA mixture (red) as well as the sample after isothermal
recrystallization at: 398 K (green), 388 K (dark blue), 378 K
(turquoise), and 368 K (violet). (b) Glass-transition temperatures of
NMS + KVA mixtures. Diamonds correspond to the experimentally
determined Tg values, while the orange pentagon (NMS) represents
the data taken from the literature. The dashed line represents the
Gordon−Taylor prediction. Empty diamonds correspond to the Tg
values obtained after recrystallization performed at (from the right
side): 368 K (violet), 373 K (black), 378 K (turquoise), 383 K
(black), 388 K (dark blue), 393 K (black), and 398 K (green).
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where ε∞ is the high-frequency limit permittivity, ε0 is the
permittivity of vacuum, Δε is the dielectric strength, ω is equal
to 2πf, τHN is the HN relaxation time, and a and b represent the
symmetric and asymmetric broadening of the relaxation peak,
respectively. Based on the fitting parameters determined above,
the values of τα were calculated by means of the following
formula





































Relaxation times, obtained from the fitting procedure
described above, are presented as circles in panel (a) of Figure
4. It can be seen that the τα(T) values determined for the
measured systems show a non-Arrhenius behavior. Therefore,














where τ∞, B, and T0 are the fitting parameters. By extrapolating
the VFT fit to 100 s, we were able to determine the Tg values
[according to the definition Tg = T(τα = 100 s)] of the
following systems: NMS, NMS + 20 wt % KVA, NMS + 30 wt
% KVA, NMS + 40 wt % KVA, NMS + 55 wt % KVA, NMS +
80 wt % KVA, and neat KVA as 291, 302, 311, 320, 334, 354,
and 376 K, respectively. The obtained results were in good
agreement with the calorimetric data, even considering the
different heating rates applied during both analyses: 10 K/min
in the case of DSC and 2 K/min in the case of BDS. The
theoretical explanation of this phenomenon as well as
calculations considering the employed experimental techniques
is well described in ref 59. Panel (b) of Figure 4 shows the
experimentally determined compositional dependence of the
Table 1. Calorimetric Glass-Transition Temperatures Determined after the Recrystallization of the Excess Amount of the Drug
from the NMS + 40 wt % KVA System at Various Temperatures and the Corresponding Drug Concentrations of the NMS +
KVA ASDs
temperature of performed recrystallization [K] 368 373 378 383 388 393 398
Tg [K] 344 ± 0.5 343 ± 0.5 342 ± 0.5 340 ± 0.5 337 ± 0.5 335 ± 0.5 330 ± 0.5
solubility limit (wt % of API in the system) 32 ± 0.2 33 ± 0.2 35 ± 0.2 37 ± 0.2 41 ± 0.2 45 ± 0.3 49 ± 0.2
Figure 3. Representative dielectric loss spectra of the amorphous
binary mixture of NMS + 40 wt % KVA above its glass-transition
temperature (from 325 to 393 K, recorded every 4 K), collected at
ambient pressure (0.1 MPa). Red lines indicate the α process.
Figure 4. (a) Relaxation map of the following systems (from the right side): NMS (orange), NMS + 20 wt % KVA (pink), NMS + 30 wt % KVA
(raspberry), NMS + 40 wt % KVA (red), NMS + 55 wt % KVA (cardinal), NMS + 80 wt % KVA (burgundy), and KVA (black). Empty circles
indicate the crystallization onset. Temperature dependences of τα in the supercooled liquid are described by the VFT equation (red solid lines). (b)
Glass-transition temperatures of NMS + KVA mixtures. The circles correspond to the experimentally determined Tg values, while the orange
pentagon (NMS) represents the data taken from the literature.47
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Tg values. As stated at the beginning of this section, this was
then used to identify the compositions obtained after the
recrystallization of the excess amount of NMS from the
supersaturated solutions.
Similar to the calorimetric measurements carried out in the
first part of this work, the initial (supersaturated) drug−
polymer composition containing 40 wt % of KVA was chosen
for the subsequent solubility studies. In the first step of our
investigations, the sample was annealed at seven different
temperatures from 368 to 398 K (every 5 K) for up to 70 h.
Panels (a,b) of Figure 5 show the dielectric spectra of the
representative examples of NMS + 40 wt % KVA during the
Figure 5. (a,b) Dielectric spectra obtained during the isothermal recrystallization determined at 373 and 383 K, respectively. t0 indicates the first
recorded spectrum at the set temperature. (c,d) Dielectric spectra obtained during additional measurements in the temperature range from 341 to
373 and 339 to 383 K, registered every 4 K, carried out after isothermal recrystallization at 373 and 383 K, respectively.
Figure 6. (a) Relaxation map of the fully amorphous system (from the right side): NMS + 40 wt % KVA (red circles), NMS + 55 wt % KVA
(cardinal circles), NMS + 80 wt % KVA (burgundy circles), and system after recrystallization at (from the right side): 398 K (green stars), 393 K
(black stars), 388 K (dark blue stars), 383 K (black stars), 378 K (turquoise stars), 373 K (black stars), and 368 K (violet stars). Temperature
dependences of τα in the supercooled liquid were described by the VFT equation (red solid lines). (b) Glass-transition temperatures of NMS +
KVA mixtures. Full circles correspond to the experimentally determined Tg values. Empty circles correspond to the Tg values obtained after
recrystallization performed at (from the right side): 368 K (violet), 373 K (black), 378 K (turquoise), 383 K (black), 388 K (dark blue), 393 K
(black), and 398 K (green).
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isothermal recrystallization performed at two temperatures:
373 and 383 K, respectively. As mentioned earlier, the
recrystallization of the amorphous material, registered during
the isothermal dielectric studies, is manifested as the drop in
the intensity of the α-process peak over time. However, in the
presented case of the recrystallization of the amorphous NMS
from the drug−polymer ASD, one can additionally notice a
shift of the structural relaxation process toward lower
frequencies. This can be explained by the decrease in the
global mobility of the system associated with an increase in the
Tg value of the ASD due to the decreasing amount of the
amorphous drug remaining in the mixture (the weakening of
the plasticization effect). This phenomenon has been observed
for systems comprising a low-Tg API and a high-Tg polymer. A
similar behavior was also observed during the recrystallization
of flutamide in the flutamide−Kollidon VA64 system,37
aripiprazole in compositions with Kollidon VA64 or
Soluplus,41 and sildenafil in the sildenafil + Kollidon VA64
ASD system.43 It is worth mentioning that the opposite
phenomenon, the shift of the α-relaxation process toward
higher frequencies during the recrystallization corresponding
to the enhancement of the plasticizing effect, can be observed
in the systems based on a high-Tg API and a low-Tg polymer
such as sildenafil + poly vinylacetate.43 When the recrystalliza-
tion of the excess amount of NMS from the supersaturated
solution had ceased, one loss peak could be observed in the
dielectric loss spectrum (see panels (a,b) of Figure 5).
Next, we performed additional experiments, in which the
sample after recrystallization was remeasured during heating to
determine the molecular dynamics of the system in a broad
temperature range [see panels (c,d) of Figure 5]. Then, the
obtained spectra were analyzed and subjected to the HN fitting
procedure to determine the temperature dependence of the
relaxation times of the NMS + KVA systems after
recrystallization (τα′(T); see panel (a) of Figure 6. To
determine Tg of the sample obtained after isothermal
recrystallization, we extrapolated the VFT fits to 100 s (Tg =
T(τα = 100 s)). The Tg values determined after the
recrystallization of the excess amount of the drug from the
NMS + 40 wt % KVA mixture are listed in Table 2.
As shown in panel (b) of Figure 6, we were able to identify
the concentrations of the systems obtained after recrystalliza-
tion by correlating the Tg value to the experimentally
determined compositional dependence of the Tg’s. The exact
values are summarized in Table 2. It can be concluded that
both sets of Tg’s and the solubility limits obtained from the
calorimetric and dielectric measurements are in excellent
agreement.
As the experimental determination of the solubility limit has
its limitations (i.e., high viscosity of the system at relatively low
temperatures),9,12,13 to obtain another estimation of the
solubility limit of NMS in the KVA matrix at room
temperature, we decided to apply one of the theoretical
approaches.
Determination of the Solubility Limits of the NMS +
KVA ASD at Ambient Pressure Conditions Using the FH
Theory. Solubility of NMS in the KVA matrix at 298 K was
determined using the F−H theory by measuring the parameter
χ (the F−H interaction parameter) from the solid−liquid line






































where Tm and Tm
0 are the melting points of the API in the
binary mixture and neat drug, respectively, R is the gas
constant, T is the temperature, ΔHfus is the heat of fusion of
the pure drug, ϕ is the volume fraction of the API (NMS), m is
the volume ratio of the polymer to drug, and χ is the F−H
interaction parameter. Note that m can be calculated as per eq










The following parameters were used in eqs 6 and 7: Tm
0 =
421 K, ΔHfus = 32,988 J/mol, ddrug = 1.41 g/cm3, dpoly = 1.20
g/cm3, Mw(drug) = 308.3 g/mol, and Mw(poly) = 46,000 g/mol.
We employed two approaches in relation to the estimation
of the χ parameter: (I) best fitting a single χ value to the
experimental data points61 and (II) determining the temper-
ature dependence of the interaction parameter χ19 (eq 8)




where A and B are constants related to entropy and enthalpy
contributions, respectively.62
Using the approach (I), we determined the χ parameter as
−1.17 ± 0.08, implying the miscibility of the drug and
polymer. The solubility of NMS in KVA at 298 K was found to
be 2.9 wt %. However, as can be seen in Figure 7, when
determining the A and B parameters [approach (II)],
estimated to be 6.695 ± 0.85 and −2996 ± 324, respectively,
the solubility of NMS in the polymer was assessed to be 14 wt
%.
Once we obtained the temperature dependence of the NMS
solubility in the KVA matrix, we moved to high-pressure
measurements to assess whether or not elevated pressure
would affect it.
Determination of the Solubility Limits of the NMS +
KVA ASD via Dielectric Measurements at Elevated
Pressure Conditions. Similar to the measurements per-
formed at atmospheric pressure presented in the previous
section, we started with the determination of the molecular
dynamics of the systems at elevated pressure conditions (at 50
MPa). The spectra exhibited one loss peak corresponding to
the structural α relaxation (data not shown). From the analysis
Table 2. Glass-Transition Temperatures Determined by BDS after the Recrystallization of the Excess Amount of the Drug
from the NMS + 40 wt % KVA System at Various Temperatures and Corresponding Drug Concentrations of the NMS + KVA
ASDs
temperature of performed recrystallization [K] 368 373 378 383 388 393 398
Tg [K] 343 ± 1.1 342 ± 1.0 341 ± 0.9 339 ± 0.8 336 ± 0.8 334 ± 0.7 330 ± 0.6
solubility limit (wt % of API in the system) 32 ± 0.9 33 ± 0.8 35 ± 0.8 37 ± 0.6 41 ± 0.5 45 ± 0.4 49 ± 0.4
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of these spectra collected above Tg, we determined the
temperature dependencies of the α-relaxation times for the
measured systems. As can be seen in panel (a) of Figure 8, we
estimated the Tg values of NMS + 20 wt % KVA, NMS + 40 wt
% KVA, and NMS + 55 wt % KVA as 314, 332, and 346 K,
respectively, from the extrapolation of VFT fit to 100 s. The
nearly constant increase in Tg (ΔT = 12 K) is consistent with
the high-pressure data obtained for another pharmaceutical,
flutamide.37,38 This behavior can be explained by the decrease
in the molecular mobility resulting from the increased
densification of molecular packing of the system as the applied
pressure raises.63,64 Observing the constant increase in Tg, we
decided to vertically displace the compositional dependence of
the Tg values obtained at ambient pressure to this relationship.
The result of this procedure can be seen in panel (b) of Figure
8. It should be mentioned that due to the equipment limitation
of the used heating circulator, not all prepared samples could
be measured, which resulted in a limited number of Tg values
determined at elevated pressures.
We next annealed the NMS + 40 wt % KVA system at 368,
378, 388, and 398 K for up to 100 h. When the recrystallization
of the excess amount of NMS from the supersaturated solution
had ceased, the samples were cooled down and then re-
measured to determine the molecular dynamics of the systems
in a broad temperature range (data not shown). By following
the procedure already discussed in this work [extrapolation of
the VFT fits to 100 s; Tg = T(τα = 100 s)], we were able to
determine the corresponding Tg’s [see panel (a) of Figure 9].
It has to be pointed out that in the case of the isothermal
recrystallization performed at 368 K, only one dielectric
spectrum could have been fitted with the acceptable accuracy
by the HN function. Thus, the number of experimentally
determined relaxation times was not sufficient to parameterize
it with the VFT equation. However, due to the close proximity
of the well-parameterized system, NMS + 40 wt % KVA, after
annealing at 378 K, we shifted its VFT fit horizontally and used
this extrapolation to determine Tg [red dashed line in panel (a)
of Figure 9]. This approach has been validated as presented in
our previous work on flutamide-based ASDs.37,38 The Tg
values determined after the recrystallization of the excess
amount of drug from the NMS + 40 wt % KVA mixture at an
elevated pressure (50 MPa) are listed in Table 3.
Finally, by comparing the obtained Tg values to the vertically
shifted concentration dependence of the Tg values of the
system obtained at ambient pressure (discussed earlier), we
identified the solubility limits determined after the recrystal-
lization of the excess amount of NMS from the supersaturated
mixture [see panel (b) of Figure 9]. We listed the relevant
values in Table 3. Based on the presented results, one can draw
a conclusion that the solubility of the drug in the polymer
Figure 7. Glass-transition temperatures of NMS + KVA mixtures.
Circles and stars correspond to the experimentally determined Tg and
solubility limit values, respectively, while orange pentagons (NMS)
represent experimental data that correspond to the literature.47
Dashed line represents drug solubility (the solid−liquid line) in the
polymer obtained using theFH theory.
Figure 8. (a) Relaxation map of the following systems (from the right side): NMS + 20 wt % KVA (pink), NMS + 40 wt % KVA (red), and NMS +
55 wt % KVA (cardinal). Empty hexagon corresponds to the crystallization onset. Temperature dependences of τα in the supercooled liquid were
described by the VFT equation (red solid lines). (b) Glass-transition temperatures of NMS + KVA mixtures. Hexagons and circles correspond to
the experimentally determined Tg values at 50 and 0.1 MPa, respectively, while orange pentagons (NMS) represent the data taken from the
literature. The dotted line is the vertically transposed relationship of the Tg dependence obtained at ambient pressure.
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matrix decreases with the increasing pressure. This is
consistent with the recently published data.37,38
By following the idea that the relaxation time is the key to
sustain the desired level of solubility while increasing the
pressure,38 we evaluated our results in this respect. By
analyzing the obtained data, it is possible to observe instances
where the recrystallization began for the same initial relaxation
time: (i) 398 K and 50 MPa and 383 K and 0.1 MPa (τα = 1.07
μs); see panel (a) of Figure 10 and (ii) 388 K and 50 MPa and
373 K and 0.1 MPa (τα = 4.92 μs); see panel (b) of Figure 10.
Figure 11 shows the solubility limit values obtained for the
data above (recrystallization performed for the same initial
Figure 9. (a) Relaxation map of the fully amorphous NMS + 55 wt % KVA (cardinal hexagon) system and systems after recrystallization at (from
the right side): 398 K (green stars), 388 K (dark blue stars), 378 K (turquoise stars), and 368 K (violet stars) at 50 MPa. The temperature
dependence of τα in the supercooled liquid was described by the VFT equation (red solid lines). The red dashed line is the horizontal displacement
of the VFT fit of the nearest parameterized concentration. (b) Glass-transition temperatures of NMS + KVA mixtures. Full hexagons correspond to
the experimentally determined Tg values at 50 MPa. Empty hexagons correspond to the Tg values obtained after recrystallization performed at
(from the left side): 368 K (violet), 378 K (turquoise), 388 K (dark blue), and 398 K (green). The dotted line is the vertically transposed
relationship of the Tg dependence obtained at ambient pressure.
Table 3. Glass-Transition Temperatures Determined by BDS after the Recrystallization of the Excess Amount of Drug from
the NMS + 40 wt % KVA System at Various Temperatures and Corresponding Drug Concentrations of the NMS + KVA ASDs
at 50 MPa
temperature of performed recrystallization [K] 368 378 388 398
Tg [K] 358 ± 2.1 357 ± 2.1 356 ± 1.7 354 ± 1.5
solubility limit (wt % of API in the system) 29 ± 1.4 31 ± 1.4 32 ± 1.1 36 ± 1.0
Figure 10. (a,b) τα(T) registered for the fully amorphous NMS + 40 wt % KVA sample (red hexagons and circles for 50 and 0.1 MPa, respectively)
as well as the sample after isothermal crystallization at: (i) 398 K and 50 MPa and (ii) 383 K and 0.1 MPa (green and black stars, respectively)for
panel (a); and (i) 388 K and 50 MPa and (ii) 373 K and 0.1 MPa (dark blue and black stars, respectively)for panel (b). τα(T) in the supercooled
liquid has been described by the VFT equation (red solid lines).
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relaxation time). Clearly, the presented result for the NMS +
KVA ASD is yet another example, confirming that regardless of
the chosen temperature or pressure conditions, there is a way
of maintaining the desired level of solubility by sustaining the
same initial relaxation time. This can contribute to a better
understanding of the role of isochronal conditions in the
solubility limit studies.
Determination of the Solubility Limits of the NMS +
KVA ASD at Elevated Pressure Conditions Using the FH
Theory. Finally, we applied the FH theory to the data
generated under elevated pressure (50 MPa). The melting
point of NMS under such a condition is 435 K,65 while the
enthalpy of drug melting and density of the components were
taken to be comparable to those obtained when no pressure
was applied. Using the approach (I), the χ parameter was
determined to be −1.3 ± 0.2, implying the miscibility of the
drug and polymer; however, it was clear that the fit is not
precise. Thus, the solubility of NMS in KVA at 298 K was
found to be 3 wt %. Using the approach (II) and allowing the
A and B parameters to fit best the experimental points, they
now became 13.03 ± 0.3 and −5511 ± 113, respectively, and
the solubility of API in the polymer was assessed to be 21.7 wt
% (see Figure 12).
Next, we decided to shift vertically the experimental data
corresponding to the solubility limits obtained at elevated
pressures. As a reference point, we used the melting
temperature of neat NMS at 5065 and 0.1 MPa.47 As can be
seen in panel (a) of Figure 13, this procedure provides an
interesting result (gray pentagons, empty and filled, respec-
tively). The data overlap nearly seamlessly. As illustrated in
panel (b) of Figure 13, the obtained set of data (generated by
shifting the high-pressure points downward to the line formed
by the experimental points at 0.1 MPa) was then fitted using
the FH model. The “global” χ parameter for this data set was
determined to be −1.41 ± 0.17, with the solubility of NMS at
298 K in the polymer equal to 3.7 wt %, slightly higher than
the values obtained when the experimental points at 0.1 and 50
MPa were fitted separately. However, it needs to be
highlighted that the quality of the fit as expressed by the R2
value was only 0.84. A better fit (R2 = 0.99) was determined
using the approach (II), where the A and B parameters were
calculated to be 10.85 ± 0.94 and −4602 ± 350, respectively,
translating into NMS solubility of 22.6%, close to the value of
solubility obtained for the high-pressure data alone. Thus,
combining the measurements from atmospheric and high-
pressure experiments can result in the widening of the data set
and adding critical points at compositions not accessible when
performing standard measurements and improving the
predictions. Janssen et al. proposed that in relation to the
pressure impact on A and B, the component related to the
enthalpy of mixing (B) is not pressure-dependent, while the
parameter A, correlated with the free volume of the mixture,
Figure 11. Experimentally determined glass-transition temperatures
for the NMS + KVA mixtures. Hexagons and circles correspond to the
experimentally determined Tg values at 50 and 0.1 MPa, respectively,
while pentagons (NMS) represent the experimental data correspond-
ing with the literature. Dotted line is the vertically transposed
relationship to the Tg dependence obtained at ambient pressure. Stars
correspond to the exact solubility limits determined during each
measurement. Light green and light blue shadowed areas correspond
to the concentrations obtained after recrystallization at isochronal, τα
= 1.07 and 4.92 μs, conditions.
Figure 12. Glass-transition temperatures of NMS + KVA mixtures.
Circles and hexagons correspond to the experimentally determined Tg
at 0.1 and 50 MPa, respectively, while empty stars correspond to the
solubility limit values determined at elevated pressures (50 MPa), and
empty pentagons (neat NMS) represent data taken from the literature
at elevated pressures.65 Dashed line represents the drug solubility in
the polymer (the solid−liquid line) determined using the FH theory.
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should decrease as an increase in pressure reduces the free
volume.66 This approach was tested here, and indeed, when
the B parameter was kept constant at −2996, as determined for
the atmospheric pressure data only (see above), the parameter
A for the whole data set combined results obtained from both
pressures, established at 5.825 ± 0.11, but it was not
statistically different to that determined for the experimental
points with no pressure effect. It appears that the 50 MPa
pressure is not high enough to significantly change the
parameter associated with a change in free volume, but as
stated above, the data points generated by shifting the high-
pressure points downward to the line formed by the
experimental points at 0.1 MPa do improve the predictions.
Based on the presented results, one can draw a conclusion
that despite the fact that the solubility at a given temperature
changes with the applied pressure, the overall profile of the
temperature dependence of the API solubility in the polymer
matrix is not pressure-sensitive. Therefore, it would seem that
by applying pressure, one can simply transpose this profile
vertically. This approach allows to obtain the solubility values
at elevated pressure conditions and transpose them to generate
more reliable data for the data points at lower temperatures
and at ambient pressure. This approach might be the long-
awaited solution to the problem of experimental determination
of the solubility limit of a drug in a polymer matrix at low
temperatures. The possibility of determining data in an
extended temperature range would further contribute to the
further development and/or verification of theoretical models.
However, this is only the first step toward the understanding of
the role of elevated pressures in the solubility limit studies.
Therefore, we strongly encourage further exploration of this
phenomenon.
■ CONCLUSIONS
To summarize, BDS investigations carried out on the NMS +
KVAs systems provided results which were in excellent
agreement with those obtained from calorimetric measure-
ments in terms of the solubility limit determination.
Furthermore, it was revealed that the solubility of the API in
the polymer matrix decreased with increasing pressure [i.e. (i)
32 and 29 wt % at 368 K and 0.1 and 50 MPa, respectively or
(ii) 49 and 36 wt % at 398 K and 0.1 and 50 MPa,
respectively]. Experiments on the ASDs confirmed that
regardless of the chosen sets of pressure or temperature
conditions, the preservation of the same initial relaxation time
is the key to maintaining the desired level of solubility, which
will contribute to a better understanding of the role of the
isochronal conditions in the solubility limit studies. Based on
the presented data, one can conclude that by vertically
transposing the results determined at elevated pressure, it is
possible to obtain the solubility limit values corresponding to
low temperatures. This may be the long-awaited solution to
some of the limitations of experimental methods for
determining drug solubility in a polymer matrix.
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